Unicycive Therapeutics, Inc.
UNCYHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Unicycive Therapeutics, Inc. focuses on Biotechnology services and products. Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. Valued at $141.3M, UNCY is a micro-cap name in its sector. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease.
Market Cap
$141.3M
Beta
1.78
P/E (TTM)
—
P/E (Fwd)
3.65
EPS (TTM)
$-1.71
EPS (Fwd)
$1.41
ROE
-101.1%
ROA
-40.6%
Cash
$61.4M
Total Debt
$671,000
Free CF
-$12.7M
52W Change
21.3%
Annual Financials
Cash vs Debt
Where UNCY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, UNCY finished 20.64% below its 150-day moving average ($6.54) and 19.28% below its 200-day moving average ($6.43). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is UNCY overbought or oversold?
At the September 3, 2026 close, UNCY's RSI(14) was 43.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Unicycive Therapeutics, Inc. holds $61.4M in cash against $671K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$12.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -101.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $951K (2022) to $0 (2025), a 100% decline worth watching.
Unicycive Therapeutics, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, UNCY has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing UNCY's risk profile alongside its fundamentals and technical indicators provides a more complete picture.